1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose

K. Park; J. S. Lee; J. Y. Han; K. H. Lee; J. H. Kim; E. K. Cho; J. Y. Cho; Y. J. Min; J. S. Kim; D. W. Kim

doi:10.1016/S1556-0864(16)30243-X

1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose

K. Park
, J. S. Lee
, J. Y. Han
, K. H. Lee
, J. H. Kim
, E. K. Cho
, J. Y. Cho
, Y. J. Min
, J. S. Kim
, D. W. Kim

Department of Internal Medicine

Seoul National University
National Cancer Center Korea
Chungbuk National University
CHA University
Gachon University
Yonsei University
University of Ulsan

Research output: Contribution to journal › Article › peer-review

41 Scopus citations

Original language	English
Pages (from-to)	S113
Journal	Journal of Thoracic Oncology
Volume	11
Issue number	4
DOIs	https://doi.org/10.1016/S1556-0864(16)30243-X
State	Published - Apr 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/S1556-0864(16)30243-X

Cite this

@article{3e7c4c4861cc4eef9b123d27a61be4f3,

title = "1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose",

author = "K. Park and Lee, \{J. S.\} and Han, \{J. Y.\} and Lee, \{K. H.\} and Kim, \{J. H.\} and Cho, \{E. K.\} and Cho, \{J. Y.\} and Min, \{Y. J.\} and Kim, \{J. S.\} and Kim, \{D. W.\}",

year = "2016",

month = apr,

doi = "10.1016/S1556-0864(16)30243-X",

language = "English",

volume = "11",

pages = "S113",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "Elsevier Inc.",

number = "4",

}

TY - JOUR

T1 - 1300

T2 - Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose

AU - Park, K.

AU - Lee, J. S.

AU - Han, J. Y.

AU - Lee, K. H.

AU - Kim, J. H.

AU - Cho, E. K.

AU - Cho, J. Y.

AU - Min, Y. J.

AU - Kim, J. S.

AU - Kim, D. W.

PY - 2016/4

Y1 - 2016/4

UR - https://www.scopus.com/pages/publications/84992503694

U2 - 10.1016/S1556-0864(16)30243-X

DO - 10.1016/S1556-0864(16)30243-X

M3 - Article

AN - SCOPUS:84992503694

SN - 1556-0864

VL - 11

SP - S113

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 4

ER -

1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose

UN SDGs

Access to Document

Other files and links

Cite this